...
首页> 外文期刊>Vaccine >Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice.
【24h】

Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice.

机译:牛痘病毒利斯特氏尾部划痕作为评估小鼠天花疫苗效力的模型。

获取原文
获取原文并翻译 | 示例
           

摘要

Since smallpox eradication by the WHO during the 1980s, potency of new vaccines is compared to vaccines that were used during the eradication campaign. In this work we characterize the tail scarification technique in mice as a model for scarification in humans. Similar to humans, mice develop "clinical take" which is dependent on the vaccination dose. Appearance of anti-Vaccinia IgM is followed by IgG antibodies 10 days post scarification and lasting more then 1(1/2) years. Mice with "clinical take" are 100% protected against lethal respiratory challenge (100LD(50)) of Vaccinia WR indicating that the "clinical take" can serve as a correlate of protective immunity. Reducing the vaccination dose and using Cowpox virus as a more virulent strain, enabled us to draw the limit of the vaccine potency in mice. Similar to humans, in revaccinated mice the development of "clinical take" was inversely correlated to the level of pre-existing antibodies. These results indicate that tail scarification of mice can be used as a model for evaluation of smallpox vaccines. High correlation between "clinical take" and protective immunity allows the use of visual inspection to evaluate vaccine potency.
机译:自世界卫生组织在1980年代根除天花以来,将新疫苗的效力与根除运动中使用的疫苗进行了比较。在这项工作中,我们将小鼠的尾巴稀疏化技术表征为人类稀疏化的模型。与人类相似,小鼠会产生“临床服用量”,这取决于疫苗接种剂量。抗痘苗IgM的出现是在疤痕消除后10天出现IgG抗体,持续时间超过1(1/2)年。具有“临床服药”的小鼠可针对牛痘WR的致命呼吸道攻击(100LD(50))进行100%的保护,表明“临床服药”可作为保护性免疫的相关物质。减少疫苗接种剂量并使用牛痘病毒作为更具毒性的毒株,使我们能够划定小鼠疫苗效力的极限。与人类相似,在重新接种的小鼠中,“临床服用量”的发展与预先存在的抗体水平成反比。这些结果表明小鼠的尾巴稀疏化可以用作评估天花疫苗的模型。 “临床服用量”与保护性免疫之间的高度相关性允许使用目视检查来评估疫苗效力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号